All In Biotech

Drug Trial Radar · NCT05629390

Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study

Randomized Controlled, Multicenter, Double-Masked, Parallel Phase III Trial to Evaluate the Efficacy and Safety of Lotilaner Ophthalmic Solution for the Treatment of Demodex Blepharitis in China With an Open-Label Pharmacokinetics Sub-Study

Last checked: Nov 20, 2026Latest source record: May 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 163 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

163

Actual

Start

Oct 23, 2022

Primary completion

Sep 15, 2023

Study completion Apr 2, 2024

Sponsor

Lead sponsor
LianBio LLCIndustry
Sponsor type
Industry
First posted
Nov 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Phase III main study is a randomized, controlled, multicenter, double blind, trial to evaluate the efficacy and safety of TP-03 (lotilaner ophthalmic solution, 0.25%), for the treatment of Demodex blepharitis in Chinese patients. The PK sub-study is a single-arm, open-label trial to evaluate systemic TP-03 in whole blood following topical ocular administration

Conditions

  • Blepharitis

Interventions

  • LotilanerDrug

    Lotilaner Ophthalmic Solution

  • Vehicle ControlDrug

    Vehicle of TP-03 ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of participants cured based on their collarette score of 0 for the upper eyelid of the analysis eye.Time frame: 43 days
  2. The proportion of participants with Demodex eradication based on the mite density of 0 mites/lash for the analysis eye at Day 43Time frame: 43 days
  3. The assessment of treatment-related adverse effectsTime frame: 43 days

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Chongqing Aier Eye Hospital

    Chongqing, Chongqing Municipality, China

  • Xiamen Eye Center of Xiamen University

    Xiamen, Fujian, China

  • Guangzhou Aier Eye Hospital

    Guangzhou, Guangdong, China

  • Zhongshan Ophthalmic Center, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Hainan Eye Hospital

    Haikou, Hainan, China

  • The First Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Henan Provincial Eye Hospital

    Zhengzhou, Henan, China

  • Union Hospital, Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Xiangya Hospital, Central South University

    Changsha, Hunan, China

  • The First Affiliated Hospital of University of South China

    Hengyang, Hunan, China

  • Wuxi Second People's Hospital

    Wuxi, Jiangsu, China

  • Eye& Ent Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

  • Shanxi Provincial Eye Hospital

    Taiyuan, Shanxi, China

  • Tianjin Medical University Eye Hospital

    Tianjin, Tianjin Municipality, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Eye Hospital, Wenzhou Medical University

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.